Antidepressants, including the selective serotonin reuptake inhibitors (SSRIs), are thought to exert their clinical effects by enhancing serotonin (5-HT) transmission. However, animal studies show that the full magnitude of this enhancement is reached only following prolonged treatments with SSRIs, consistent with the well-described therapeutic delay of this class of medications. Thus, the clinical efficacy of SSRIs most likely does not emerge from their acute pharmacological actions, but rather indirectly from cellular alterations that develop over the course of a sustained treatment. Here, we show that sustained administration of the SSRI citalopram leads to a homeostatic-like increase in the strength of excitatory glutamate synapses onto 5-HT neurons of the dorsal raphe nucleus that was apparent following one week of treatment. A shorter treatment with citalopram rather induced a paradoxical decrease in the strength of these synapses, which manifested itself by both pre- and postsynaptic mechanisms. As such, these results show that an SSRI treatment induced a concerted and time-dependent modulation of the synaptic drive of 5-HT neurons, which are known to be critically involved in mood regulation. This regulation, and its time course, provide a mechanistic framework that may be relevant not only for explaining the therapeutic delay of antidepressants, but also for the perplexing increases in suicide risks reportedly occurring early in the course of antidepressant treatments.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.neuropharm.2015.02.027 | DOI Listing |
J Neurosci Res
January 2025
Centre for Neuroscience, Department of Biotechnology, Cochin University of Science and Technology, Kochi, Kerala, India.
Parkinson's Disease (PD) is a neurodegenerative disorder marked by the depletion of dopaminergic neurons. Recent studies highlight the gut-liver-brain (GLB) axis and its role in PD pathogenesis. The GLB axis forms a dynamic network facilitating bidirectional communication between the gastrointestinal tract, liver, and central nervous system.
View Article and Find Full Text PDFJ Neurosci
January 2025
Leibniz Institute for Neurobiology (LIN), Department of Genetics of Learning and Memory, Magdeburg, 39118 Germany
For a proper representation of the causal structure of the world, it is adaptive to consider both evidence for and evidence against causality. To take punishment as an example, the causality of a stimulus is unlikely if there is a temporal gap before punishment is received, but causality is credible if the stimulus immediately precedes punishment. In contrast, causality can be ruled out if the punishment occurred first.
View Article and Find Full Text PDFBackground: The limited treatment options for Alzheimer's emphasizes the need to explore novel drug targets and bring new therapeutics to market. Drug repurposing is an efficient route to bring a safe and effective treatment to the clinic. Agomelatine (AGO) was identified by a high-throughput drug screening algorithm as having mechanistic potential to treat Alzheimer's.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Cleveland Clinic, Cleveland, OH, USA.
Background: Alzheimer's Disease (AD) risk variants APOE4 and TREM2-R47H have been shown to impact glial cell functions and transcriptional profiles. We hypothesize that TREM2-APOE may have synergistic effects in driving pathogenesis and disease progression of AD in a cell type-specific manner.
Methods: We investigated cell-type specific transcriptional changes associated with APOE4- and TREM2-R47H-carrier status.
Alzheimers Dement
December 2024
Johns Hopkins University, Baltimore, MD, USA.
Background: By 2050 the number of Alzheimer's Disease (AD) patients is projected to exceed 150 million worldwide. AD is an incurable, insufficiently understood, and devastating neurodegenerative disease, with high patient heterogeneity in terms of progression, clinical manifestation (including neuropsychiatric symptoms, NPS) and, importantly, responsiveness to treatment options.[1] In the last 20 years, 98% of clinical trials for AD have failed, highlighting the urgent need to drastically change pre-clinical research to develop better predictors of drug safety and effectiveness.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!